DOI: 10.4244/EIJ-D-18-00500R

Reply to the letter to the editor “Is transcatheter aortic valve implantation feasible in patients with chronic kidney disease?”

Tali Steinmetz*, MD; Guy Witberg, MD

We appreciate the interest in our article. The authors (Doshi et al)1 raised a few concerns that we will clarify below.

1. The results are not accompanied by the Society of Thoracic Surgeons (STS) score or EuroSCORE II which are major determinants for a decision to perform TAVI in most cases.

The mean (±SD) STS of the CKD patients who underwent TAVR was 8.8±3.7. As for the conservative treatment group, most of these patients were not presented to the institutional Heart Team for consideration of TAVI so we do not have the STS or EuroSCORE II data for these patients. We agree that this is a potential source of bias, as mentioned in the manuscript, but we did undertake several measures to prevent most of the sources for such bias. First, we did not include patients who were judged by their attending physicians to be suffering from cognitive decline or had an active malignancy in the conservative treatment arm. Second, we used several statistical measures to adjust for differences in baseline characteristics between the two groups – Cox proportional hazards model with adjustment for multiple variables, propensity score matching and inverse probability weighting. All three methods yielded similar consistent and highly significant results.

2. All-cause mortality for the conservative group may not be sufficient. The authors need to include cardiovascular mortality as well.

Since overall mortality in the overall TAVI population is significant (over 20% for one year2 and over 60% for five years3), we believe that the relevant endpoint for patients referred for TAVI is overall rather than cause-specific mortality. This was also the endpoint used in the landmark TAVI RCTs.

3. How many patients were already on dialysis prior to the study? Additional information is warranted as to how many patients had acute kidney injury post TAVI and how many received dialysis post TAVI.

None of the patients included in our study was receiving haemodialysis prior to TAVI and no patient was started on haemodialysis during the follow-up period.

4. Did any patient receive TAVI or surgical repair/replacement after diagnosis of aortic stenosis in the conservative management group?

As detailed in the Methods section, in order to be included in the conservative treatment group, patients had to have a documentation of severe symptomatic AS and no evidence of undergoing any intervention to the aortic valve, either TAVI or SAVR.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 14 Number 17
Apr 16, 2019
Volume 14 Number 17
View full issue


Key metrics

Suggested by Cory

10.4244/EIJ-D-18-00500L Apr 16, 2019
Is transcatheter aortic valve implantation feasible in patients with chronic kidney disease?
Doshi R and Shah J
free

CLINICAL RESEARCH

10.4244/EIJ-D-18-00058 Aug 3, 2018
Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients
Steinmetz T et al
free

10.4244/EIJV15I17A268 Apr 17, 2020
Transcatheter aortic valve implantation in nonagenarians – old…but not obsolete!
Grube E and Sinning J
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved